FIRSTNCT06399809
Fisetin to Reduce Senescence and Mobility Impairment in PAD
At risk: Primary completion moved at least 7 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Nov 2026 to Jun 30, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 30 words
- Study completion pushed from Jun 2027 to Aug 31, 2027
- Secondary endpoints: details revised at 3 of 4 entries
- Site contact updated
- Minor Site contact updatedv4
Notable Start date: Jul 16, 2024 to Sep 30, 2024v3 Show 5 more changesShow less
- Eligibility criteria expanded, about 30 words
- Primary completion date: Nov 30, 2026 to Nov 2026
- Study completion date: Jun 30, 2027 to Jun 2027
- Site contact updated
- Study description shortened, about 1 word
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Eligibility criteria expanded, about 11 words
- Start date changed from estimate of Jun 1, 2024 to Jul 16, 2024
- Secondary endpoints: details revised at 1 of 4 entries
- Study description revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Sharp Clinical Services will provide fisetin (100 mg capsules). Randomized participants will receive fisetin 20 mgs/kg once daily for two days, followed by 12 days without therapy. Fisetin will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.
Sharp Clinical Services will provide placebo (100 mg capsules). Randomized participants will receive placebo 20 mgs/kg once daily for two days, followed by 12 days without therapy. Placebo will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.
Drugs: Fisetin, Placebo
Sites
1 site in 1 country
- Northwestern University Feinberg School of MedicineChicago, Illinois, United States